ClinVar Miner

Submissions for variant NM_000527.5(LDLR):c.1817C>A (p.Ala606Asp)

gnomAD frequency: 0.00001  dbSNP: rs1410295777
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen Familial Hypercholesterolemia Variant Curation Expert Panel RCV000508835 SCV002506392 uncertain significance Hypercholesterolemia, familial, 1 2022-02-10 reviewed by expert panel curation The NM_000527.5 (LDLR): c.1817C>A (p.Ala606Asp) variant is classified as Uncertain significance for Familial Hypercholesterolemia by applying evidence codes (PM2, PP3) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows: PM2 Met: PopMax MAF = 0.00002637in European (non-Finnish) population in gnomAD (gnomAD v2.1.1). PP3 Met: REVEL = 0.756, which is above the threshold of 0.75. There are two other variants in same codon: LDLR: NM_000527:c1816G>T (p.Ala606Ser), LDLR: NM_000527:c.1816G>A (p.Ala606Thr), which are classified as Uncertain significance by these guidelines. Therefore PM5 is not met.
Labcorp Genetics (formerly Invitae), Labcorp RCV001865664 SCV002221135 uncertain significance Familial hypercholesterolemia 2021-09-17 criteria provided, single submitter clinical testing This sequence change replaces alanine with aspartic acid at codon 606 of the LDLR protein (p.Ala606Asp). The alanine residue is highly conserved and there is a moderate physicochemical difference between alanine and aspartic acid. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with LDLR-related conditions. ClinVar contains an entry for this variant (Variation ID: 440663). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002413393 SCV002714123 uncertain significance Cardiovascular phenotype 2022-03-31 criteria provided, single submitter clinical testing The p.A606D variant (also known as c.1817C>A), located in coding exon 12 of the LDLR gene, results from a C to A substitution at nucleotide position 1817. The alanine at codon 606 is replaced by aspartic acid, an amino acid with dissimilar properties. This alteration was detected in a cohort of 29,906 healthy individuals who underwent multigene panel testing (Grzymski JJ et al. Nat Med, 2020 08;26:1235-1239). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Color Diagnostics, LLC DBA Color Health RCV001865664 SCV004359043 uncertain significance Familial hypercholesterolemia 2023-05-03 criteria provided, single submitter clinical testing This missense variant (also known as p.Ala585Asp in the mature protein) replaces alanine with aspartic acid at codon 606 of the LDLR protein. Computational prediction suggests that this variant may have a deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with familial hypercholesterolemia (PMID: 17094996). This variant has been identified in 3/251478 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
All of Us Research Program, National Institutes of Health RCV000508835 SCV004822504 uncertain significance Hypercholesterolemia, familial, 1 2023-06-15 criteria provided, single submitter clinical testing This missense variant (also known as p.Ala585Asp in the mature protein) replaces alanine with aspartic acid at codon 606 of the LDLR protein. Computational prediction suggests that this variant may have a deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with familial hypercholesterolemia (PMID: 17094996). This variant has been identified in 3/251478 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Laboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde, Academisch Medisch Centrum RCV000508835 SCV000606522 pathogenic Hypercholesterolemia, familial, 1 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.